Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer’s Disease Using GLP-1 Agonists and Combinations

Rhea-AI Summary

Coya Therapeutics (NASDAQ: COYA) announced that CEO Arun Swaminathan and Dr. Stanley H. Appel will participate in a BTIG-hosted KOL webcast titled "Is Alzheimer's next for GLP-1s and Combos?" on February 27, 2025. The discussion, moderated by Juliette Lafille of BTIG, will explore the potential of GLP-1 agonists and combination therapies for treating Alzheimer's disease.

Key topics will include:

• Potential for GLP-1s to slow cognitive decline in Alzheimer's
• Effects on brain metabolism and neuroinflammation reduction
• Efficacy through combinations
• Future development pathways

Coya recently expanded its pipeline with COYA 303, an investigational biologic combining COYA 301 (proprietary low-dose interleukin-2) with a GLP-1 receptor agonist designed for subcutaneous administration to treat inflammatory diseases.

Positive

• Coya Therapeutics is expanding its pipeline to include potential Alzheimer's disease treatments
• The company is exploring innovative combination therapies with GLP-1 agonists
• Participation in the BTIG KOL webcast increases visibility for Coya's research approach
• COYA 303 represents a novel approach combining immunomodulation with metabolic regulation

Negative

• No specific clinical trial data for COYA 303 in Alzheimer's disease was mentioned
• The timeline for potential Alzheimer's disease treatments remains unclear
• Competition in the GLP-1 and Alzheimer's space is increasing rapidly
• Regulatory approval pathways for combination therapies can be complex

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Dr. Stanley H. Appel, Professor of Neurology, Houston Methodist Hospital will participate in a BTIG hosted KOL webcast “Is Alzheimer’s next for GLP-1s and Combos?” on February 27, 2025 to discuss the potential treatment of Alzheimer’s disease using GLP-1 agonists and combination therapy. Juliette Lafille, Managing Director, Healthcare Sector Specialist at BTIG, will moderate the discussion.

The topics of the discussion will include:

• Potential for GLP-1s to slow cognitive decline in Alzheimer’s Disease

• GLP-1s effect on brain metabolism, phospho-tau accumulation inhibition, neuroinflammation reduction, and neuronal branching promotion

• GLP-1s efficacy in Alzheimer’s Disease through combinations

• Discussion and path forward

Coya recently announced the expansion of its investigational pipeline and advancement of COYA 303 for the treatment of inflammatory diseases. COYA 303 is an investigational biologic combination of COYA 301 (the Company’s proprietary low-dose interleukin-2) and a GLP-1 receptor agonist designed for subcutaneous administration.

About Coya Therapeutics, Inc.

Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.

Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

COYA 302 – the Company’s lead biologic investigational product or “Pipeline in a Product”– is a proprietary combination of COYA 301 (Coya’s proprietary LD IL-2) and CTLA4-Ig for subcutaneous administration with a unique dual mechanism of action that is now being developed for the treatment of Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Parkinson’s Disease, and Alzheimer’s Disease. Its multi-targeted approach enhances the number and anti-inflammatory function of Tregs and simultaneously lowers the expression of activated microglia and the secretion of pro-inflammatory mediators. This synergistic mechanism may lead to the re-establishment of immune balance and amelioration of inflammation in a sustained and durable manner that may not be achieved by either low-dose IL-2 or CTLA4-Ig alone.

COYA-303- is an investigational biologic combination of COYA 301 (the Company’s proprietary low-dose interleukin-2) and a GLP-1 receptor agonist designed for subcutaneous administration.

For more information about Coya, please visit www.coyatherapeutics.com

Forward-Looking Statements

This press release contains “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements.

Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the clinical development and/or commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; ; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250225220869/en/

Investor Contact

David Snyder, CFO

david@coyatherapeutics.com



CORE IR

Bret Shapiro

brets@coreir.com

561-479-8566



Media Contacts

For Coya Therapeutics:

Kati Waldenburg

media@coyatherapeutics.com

212-655-0924

Source: Coya Therapeutics, Inc.

FAQ

What is COYA 303 and how might it impact Alzheimer's treatment?

COYA 303 is Coya Therapeutics' investigational biologic combining COYA 301 (low-dose interleukin-2) with a GLP-1 receptor agonist for subcutaneous administration. It's being developed for inflammatory diseases and may potentially address neuroinflammation in Alzheimer's, though specific Alzheimer's trials haven't been announced yet.

When will Coya Therapeutics (COYA) present their Alzheimer's disease GLP-1 research?

Coya Therapeutics will participate in a BTIG-hosted KOL webcast discussing GLP-1 agonists and combination therapies for Alzheimer's disease on February 27, 2025.

How does Coya Therapeutics approach regulatory T cell function for Alzheimer's treatment?

Coya Therapeutics develops biologics to enhance regulatory T cell (Treg) function. Their approach includes COYA 303, which combines low-dose interleukin-2 (to boost Tregs) with a GLP-1 receptor agonist, potentially addressing neuroinflammation in Alzheimer's disease.

What mechanisms will COYA discuss regarding GLP-1 agonists' effects on Alzheimer's disease?

COYA will discuss GLP-1 agonists' potential to slow cognitive decline through effects on brain metabolism, inhibition of phospho-tau accumulation, reduction of neuroinflammation, and promotion of neuronal branching.

Who are the key speakers at the COYA Alzheimer's GLP-1 discussion event?

The key speakers are Arun Swaminathan (Coya Therapeutics CEO), Dr. Stanley H. Appel (Professor of Neurology at Houston Methodist Hospital), and moderator Juliette Lafille (Managing Director at BTIG).

What is the connection between COYA's regulatory T cell research and GLP-1 agonists?

Coya Therapeutics is exploring the combination of their regulatory T cell enhancing technology (COYA 301, a low-dose interleukin-2) with GLP-1 receptor agonists in COYA 303, potentially creating synergistic effects to address neuroinflammation in conditions like Alzheimer's.